Advertisement

Hypofractionated Boost to the Dominant Tumor Region With Intensity Modulated Stereotactic Radiotherapy for Prostate Cancer: A Sequential Dose Escalation Pilot Study

Published:November 11, 2009DOI:https://doi.org/10.1016/j.ijrobp.2009.07.1689

      Purpose

      To evaluate the feasibility, tolerability, and preliminary outcomes in patients with prostate cancer treated according to a hypofractionated dose escalation protocol to boost the dominant tumor-bearing region of the prostate.

      Methods and Materials

      After conventional fractionated external radiotherapy to 64 to 64.4Gy, 50 patients with nonmetastatic prostate cancer were treated with an intensity-modulated radiotherapy hypofractionated boost under stereotactic conditions to a reduced prostate volume to the dominant tumor region. A rectal balloon inflated with 60cc of air was used for internal organ immobilization. Five, 8, and 8 patients were sequentially treated with two fractions of 5, 6, or 7Gy, respectively (normalized total dose in 2Gy/fraction [NTD2Gy] < 100Gy, low-dose group), whereas 29 patients received two fractions of 8Gy each (NTD2Gy > 100Gy, high-dose group). Androgen deprivation was given to 33 patients. Acute and late toxicities were assessed according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scoring system.

      Results

      Two patients presented with Grade 3 acute urinary toxicity. The 5-year probabilities of ≥Grade 2 late urinary and late low gastrointestinal (GI) toxicity–free survival were 82.2% ± 7.4% and 72.2% ± 7.6%, respectively. The incidence and severity of acute or late toxicities were not correlated with low- vs. high-dose groups, pelvic irradiation, age, or treatment with or without androgen deprivation. The 5-year biochemical disease–free survival (b-DFS) and disease-specific survival were 98% ± 1.9% and 100%, respectively.

      Conclusion

      Intensity-modulated radiotherapy hypofractionated boost dose escalation under stereotactic conditions was feasible, and showed excellent outcomes with acceptable long-term toxicity. This approach may well be considered an alternative to high-dose-rate brachytherapy.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hanks G.E.
        • Martz K.L.
        • Diamond J.J.
        The effect of dose on local control of prostate cancer.
        Int J Radiat Oncol Biol Phys. 1988; 15: 1299-1306
        • Zelefsky M.J.
        • Leibel S.A.
        • Gaudin P.B.
        • et al.
        Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 491-500
        • Vicini F.A.
        • Abner A.
        • Baglan K.L.
        • et al.
        Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?.
        Int J Radiat Oncol Biol Phys. 2001; 51: 1200-1208
        • Fiveash J.B.
        • Hanks G.
        • Roach M.
        • et al.
        3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review.
        Int J Radiat Oncol Biol Phys. 2000; 47: 335-342
        • Hanks G.E.
        • Hanlon A.L.
        • Epstein B.
        • Horwitz E.M.
        Dose response in prostate cancer with 8–12 years' follow-up.
        Int J Radiat Oncol Biol Phys. 2002; 54: 427-435
        • Kupelian P.
        • Kuban D.
        • Thames H.
        • et al.
        Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995.
        Int J Radiat Oncol Biol Phys. 2005; 61: 415-419
        • Sathya J.R.
        • Davis I.R.
        • Julian J.A.
        • et al.
        Randomized trial comparing Iridium implants plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.
        J Clin Oncol. 2005; 23: 1192-1199
        • Pollack A.
        • Zagars G.K.
        • Starkschall G.
        • et al.
        Prostate cancer radiation dose response: Results of the M.D. Anderson Phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
        • Zietman A.L.
        • DeSilvio M.L.
        • Slater J.D.
        • et al.
        Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. A randomized controlled trial.
        J Am Med Assoc. 2005; 294: 1233-1239
        • Zelefsky M.L.
        • Fuks Z.
        • Hunt M.
        • et al.
        High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116
        • Kupelian P.A.
        • Willoughby T.R.
        • Reddy C.H.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience.
        J Clin Oncol. 2007; 68: 1424-1430
        • Åstrom L.
        • Pedersen D.
        • Mercke C.
        • et al.
        Long-term outcome of high-dose rate brachytherapy in radiotherapy of localised prostate cancer.
        Radiother Oncol. 2005; 74: 151-157
        • Demanes D.J.
        • Rodriguez R.R.
        • Schour L.
        • et al.
        High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1306-1316
        • Duchesne G.M.
        • Williams S.G.
        • Das R.
        • Tai K.H.
        Patterns of toxicity following high-dose rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results.
        Radiother Oncol. 2007; 84: 128-134
        • Galalae R.M.
        • Kovács G.
        • Schultze J.
        • et al.
        Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 52: 81-90
        • Hoskin P.J.
        • Motohashi K.
        • Bownes P.
        • et al.
        High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial.
        Radiother Oncol. 2007; 84: 114-120
        • Martin T.
        • Roddiger S.
        • Kurek R.
        • et al.
        3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
        Radiother Oncol. 2004; 71: 35-41
        • Brenner D.J.
        • Martinez A.A.
        • Edmundson G.K.
        • et al.
        Direct evidence that prostate tumors show high sensitivity to fractionation (low alfa/beta ratio) similar to late-responding normal tissue.
        Int J Radiat Oncol Biol Phys. 2002; 52: 6-13
        • Brenner D.J.
        Hypofractionation for prostate cancer radiotherapy—what are the issues.
        Int J Radiat Oncol Biol Phys. 2003; 57: 912-914
        • Logue J.P.
        • Hendry J.H.
        Hypofractionation for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2001; 49: 152
        • Cheng M.E.
        • Johnston D.A.
        • Tang K.
        • et al.
        Detailed mapping of prostate carcinoma foci: Biopsy strategy implications.
        Cancer. 2000; 89: 1800-1809
        • Parker C.
        • Warde P.
        • Catton C.
        Salvage radiotherapy for PSA failure after radical prostatectomy.
        Radiother Oncol. 2001; 61: 107-116
        • Ares C.
        • Popowski Y.
        • Pampallona S.
        • et al.
        Hypofractionated boost with high-dose rate brachytherapy and open MRI-guided implants for locally aggressive prostate cancer: A sequential dose escalation pilot study.
        Int J Radiat Oncol Biol Phys. 2009 Feb 26; ([Epub ahead of print])
        • Roach M.
        • Marquez C.
        • Yuo H.-S.
        • et al.
        Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 1993; 28: 33-37
        • Bieri S.
        • Miralbell R.
        • Nouet P.
        • et al.
        Reproducibility of conformal radiation therapy in localized carcinoma of the prostate without rigid immobilization.
        Radiother Oncol. 1996; 38: 223-230
        • Soete G.
        • Verellen D.
        • Michielsen D.
        • et al.
        Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 54: 948-952
        • Miralbell R.
        • Mollà M.
        • Arnalte R.
        • et al.
        Target repositioning optimization in prostate cancer: Is intensity modulation radiotherapy under stereotactic conditions feasible?.
        Int J Radiat Oncol Biol Phys. 2004; 59: 366-371
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        J Am Med Assoc. 1998; 280: 969-974
        • Cox J.D.
        • Stetz J.
        • Pajak T.F.
        Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Roach III, M.
        • Hanks G.
        • Thames Jr., H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Kaplan E.L.
        • Meier P.
        Nonparametric Estimation from Incomplete Observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Kuban D.
        • Pollack A.
        • Huang E.
        • et al.
        Hazards of dose escalation in prostate cancer radiotherapy.
        Int J Radiat Oncol Biol Phys. 2003; 57: 1260-1268
        • Dearnaley D.P.
        • Hall E.
        • Lawrence D.
        • et al.
        Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
        British Journal of Cancer. 2005; 92: 488-498
        • Kauczor H.-U.
        • Zechmann C.
        • Stieltjes B.
        • Weber M.-A.
        Functional magnetic resonance imaging for definig the biological target volume.
        Cancer Imaging. 2006; 6: 51-55
        • Hara T.
        • Kosaka N.
        • Kishi H.
        PET imaging of prostate cancer using carbon-11 choline.
        J Nucl Med. 1998; 39: 990-995
        • Oyama N.
        • Akino H.
        • Kanamaru H.
        • et al.
        11C Acetate PET Imaging of Prostate Cancer.
        J Nucl Med. 2002; 43: 181-186
        • Price D.T.
        • Coleman E.
        • Liao R.P.
        • et al.
        Comparison of 18F Fluorocholine and 18F Fluorodeoxyglucose for positron emission tomography of androgen dependents and androgen independent prostate cancer.
        J Urol. 2002; 168: 273-280
        • Lee N.Y.
        • Mechalakos J.G.
        • Nehmeh S.
        • et al.
        Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study.
        Int J Radiat Oncol Biol Phys. 2008; 70: 2-13

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.